Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02052752 · ClinicalTrials.gov registry record · Phase 4
A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
NCT02052752: Completed Phase 4 study, sponsored by GlaxoSmithKline.
NCT02052752 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 90 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02052752, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
Study Summary
5 Day study to assess how quickly a topical acne product begins to work.
Primary Outcome
The Investigator assessed and score each target lesion's swelling (elevation), elevation scores were the actual dimensions, i.e. the value in millimeters at the lesion's highest points. Percent change in height of all three target lesions were calculated and averaged for each participant. The average lesion height at baseline was calculated for each participant. An analysis of covariance (ANCOVA) was performed with average percentage change in target lesion height as the response variable, treat
Interventions
- DRUG 3% Benzoyl Peroxide
- DRUG 3% Benzoyl Peroxide Placebo
- DRUG Neutrogena Rapid Clear®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-05 |
| Phase | Phase 4 |
What the finished NCT02052752 record still lists
NCT02052752 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 3 interventions - of which 3% Benzoyl Peroxide is the first listed.
NCT02052752 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02052752 about?
NCT02052752 is a clinical study titled "A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions". 5 Day study to assess how quickly a topical acne product begins to work.
What is the current status of trial NCT02052752?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2014-02. Estimated completion is 2014-05.
What interventions are being tested in trial NCT02052752?
The interventions under investigation include: 3% Benzoyl Peroxide (DRUG), 3% Benzoyl Peroxide Placebo (DRUG), Neutrogena Rapid Clear® (DRUG).
Who is sponsoring clinical trial NCT02052752?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02052752's enrollment target sits among peer trials
90 886th of 2000 higher than 1,088 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia